Brain Scientific Inc. (BRSF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.36: the stock has moved about 64% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBrain Scientific Inc. (BRSF) trades at $0.0006. Brain Scientific Inc. is a medtech company focused on neurology-based medical devices. Their key product offerings include the NeuroCap EEG system and NeuroNet Cloud data platform. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BRSF: BRSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BRSF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BRSF: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Brain Scientific Inc. (BRSF) Healthcare & Pipeline Overview
Brain Scientific Inc. develops and markets neurology-focused medical devices, including the NeuroCap EEG system and NeuroNet Cloud platform. Operating in the competitive medical device sector, the company targets improved EEG technology and data analysis solutions for neurological applications, while navigating the challenges of a small-cap, OTC-listed entity.
What Is the Investment Thesis for BRSF?
Brain Scientific Inc. presents a speculative investment opportunity within the medical device sector. The company's NeuroCap and NeuroEEG products target the EEG market, offering potential improvements in usability and data analysis. With a market capitalization of $0.00B, the company is a micro-cap stock trading on the OTC market, implying higher risk and volatility. A key value driver is the potential adoption of NeuroCap and NeuroEEG by hospitals and clinics seeking more efficient EEG solutions. Growth catalysts include potential FDA approvals for new products and expansion of the NeuroNet Cloud platform. However, the company's negative profit margin of -5753.0% and reliance on OTC markets are significant risk factors. Investors should carefully consider the company's financial position and competitive landscape before investing.
Based on FMP financials and quantitative analysis
BRSF Key Highlights
Market Cap of $0.00B reflects its micro-cap status and potential for high volatility.
- Gross Margin of 25.3% indicates the profitability of its products before operating expenses.
- Profit Margin of -5753.0% highlights significant challenges in achieving overall profitability.
- Beta of 0.36 suggests lower volatility compared to the overall market.
- Operates in the medical device industry, focusing on neurology-based solutions.
Who Are BRSF's Competitors?
BRSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RDGL Vivos Inc. | $0.05 | +0.24% | $24.6M | 619-signal |
| SNWV SANUWAVE Health, Inc. | $4.00 | -0.99% | $34.4M | 365-pillar |
| HYPD Hyperion DeFi, Inc. | $3.59 | -2.18% | $54.4M | 365-pillar |
| LNSR LENSAR, Inc. | $7.74 | -3.85% | $95.1M | 485-pillar |
| APYX Apyx Medical Corporation | $2.89 | -5.25% | $122M | 365-pillar |
| JMDMF Japan Medical Dynamic Marketing, Inc. | $5.00 | 0.00% | $132M | 499-signal |
| INGN Inogen, Inc. | $5.18 | -1.71% | $140M | 365-pillar |
| ELMD Electromed, Inc. | $26.65 | -1.55% | $221M | 875-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BRSF's Key Strengths?
Innovative NeuroCap design.
- NeuroNet Cloud platform for data analysis.
- Focus on neurology provides specialization.
- Proprietary technology and intellectual property.
What Are BRSF's Weaknesses?
Small market capitalization and limited resources.
- Negative profit margin and financial instability.
- Reliance on OTC markets.
- Limited brand recognition.
What Could Drive BRSF Stock Higher?
Potential FDA approvals for new products or enhancements to existing products.
- Expansion of the NeuroNet Cloud platform and its integration with other healthcare systems.
- Strategic partnerships with hospitals and clinics to expand market reach.
- International expansion into new markets.
- Development of new EEG applications beyond traditional diagnostics.
What Are the Key Risks for BRSF?
Financial-distress signal — its Altman Z-Score of -6.81 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger, established medical device companies.
- Regulatory hurdles and compliance requirements for medical devices.
- Technological obsolescence and the emergence of competing technologies.
- Limited financial resources and negative profit margin.
- Reliance on OTC markets and the associated risks of limited liquidity and transparency.
What Are the Growth Opportunities for BRSF?
- Expansion of NeuroNet Cloud Platform: The NeuroNet Cloud platform offers a significant growth opportunity by providing data analytics and storage solutions for EEG data. The market for cloud-based healthcare solutions is expanding rapidly, driven by the increasing adoption of electronic health records and the need for data-driven insights. By expanding the capabilities of NeuroNet Cloud and integrating it with other healthcare systems, Brain Scientific can attract new customers and generate recurring revenue streams. Timeline: Ongoing, with continuous updates and feature additions planned.
- FDA Approvals for New Products: Obtaining FDA approvals for new products and enhancements to existing products is crucial for Brain Scientific's growth. Regulatory approvals validate the safety and efficacy of the company's devices, allowing them to be marketed and sold to healthcare providers. The timeline for FDA approvals can vary depending on the complexity of the device and the regulatory pathway chosen. Successful approvals can significantly boost the company's revenue and market share. Timeline: Ongoing, with submissions planned for various products.
- Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Brain Scientific with access to a wider customer base and valuable feedback on its products. These partnerships can involve pilot programs, joint research projects, and co-marketing initiatives. By collaborating with healthcare providers, Brain Scientific can demonstrate the value of its products and build long-term relationships. Timeline: Ongoing, with active outreach to potential partners.
- International Expansion: Expanding into international markets represents a significant growth opportunity for Brain Scientific. The global market for medical devices is vast, and many countries have a growing need for advanced neurological solutions. By obtaining regulatory approvals in key international markets and establishing distribution networks, Brain Scientific can diversify its revenue streams and reduce its reliance on the US market. Timeline: Potential, with initial focus on select international markets.
- Development of New EEG Applications: Exploring new applications for EEG technology beyond traditional diagnostics can unlock new growth opportunities for Brain Scientific. This could involve developing EEG-based solutions for monitoring sleep disorders, assessing cognitive function, or providing neurofeedback therapy. By expanding the applications of its technology, Brain Scientific can reach new customer segments and establish itself as a leader in the field of EEG innovation. Timeline: Ongoing, with research and development efforts focused on new applications.
What Are BRSF's Competitive Advantages?
- Proprietary NeuroCap design offers potential advantages in usability and comfort.
- NeuroNet Cloud platform provides a data analytics and storage solution that can create customer stickiness.
- Focus on neurology provides specialization and expertise in a niche market.
- Intellectual property protection through patents and trademarks.
What Does BRSF Do?
Founded in 2013 and headquartered in Sarasota, Florida, Brain Scientific Inc. is a medtech company specializing in neurology-focused medical devices. The company's core mission is to innovate and provide advanced solutions for the diagnosis and monitoring of neurological conditions. Its key product, NeuroCap, is a disposable EEG cap designed to improve the efficiency and accuracy of electroencephalography procedures. NeuroCap aims to address the limitations of traditional EEG systems by offering a more comfortable and user-friendly experience. Complementing NeuroCap is NeuroEEG, a clinical-grade device used to acquire, record, transmit, and display electrical brain activity in patients of all ages. The company also offers NeuroNet Cloud, a platform for storing and analyzing brain data, providing clinicians with tools for enhanced diagnostics and research. Beyond its neurology focus, Brain Scientific also develops motor platforms, including an ultra-precise micro dosing pump and other motion products. The company operates primarily in the United States, targeting hospitals, clinics, and research institutions. Brain Scientific's strategy centers on combining innovative hardware with data analytics to improve patient outcomes in neurology.
What Products and Services Does BRSF Offer?
- Develops and markets the NeuroCap, a disposable EEG cap designed for improved comfort and ease of use.
- Offers NeuroEEG, a clinical-grade device for recording and displaying electrical brain activity.
- Provides NeuroNet Cloud, a platform for storing and analyzing EEG data.
- Develops motor platforms, including micro dosing pumps.
- Focuses on neurology-based medical devices.
- Aims to improve the efficiency and accuracy of EEG procedures.
How Does BRSF Make Money?
- Sells NeuroCap and NeuroEEG devices to hospitals, clinics, and research institutions.
- Generates revenue from subscriptions to the NeuroNet Cloud platform.
- Potentially generates revenue from the sale of motor platforms and related products.
- Focuses on direct sales and partnerships with distributors.
What Industry Does BRSF Operate In?
Brain Scientific Inc. operates within the medical device industry, specifically targeting the neurology segment. The EEG market, in particular, is expected to grow as neurological disorders become more prevalent. Brain Scientific competes with larger, established medical device companies, as well as smaller, specialized firms. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products to healthcare providers.
Who Are BRSF's Key Customers?
- Research institutions
- Neurologists
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 49 |
| 2026-08-26 | 49 |
| 2026-08-29 | 49 |
| 2026-09-01 | 49 |
| 2026-09-04 | 49 |
| 2026-09-07 | 49 |
| 2026-09-10 | 49 |
What changed?
The score has stayed at 49.
Over the same 18 days the stock moved +0.0%.
Insider Activity
The most recent 10 insider filings for Brain Scientific Inc. break down as 2 sales and 8 purchases. On net that is roughly 22.7M shares acquired (about $683K) — insiders putting money in tends to read as conviction.
Financial Health
Brain Scientific Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.81 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Brain Scientific Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Sarasota, US. The company is led by CEO Hassan Kotob. BRSF has traded publicly since 2021.
BRSF Financials
Bull Case vs Bear Case
Bull Case
- Innovative NeuroCap design.
- NeuroNet Cloud platform for data analysis.
- Focus on neurology provides specialization.
- Proprietary technology and intellectual property.
Bear Case
- Small market capitalization and limited resources.
- Negative profit margin and financial instability.
- Reliance on OTC markets.
- Limited brand recognition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BRSF Latest News
-
Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism
Yahoo! Finance: BRSF News · Feb 5, 2026
BRSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BRSF.
Price Targets
Wall Street price target analysis for BRSF.
BRSF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BRSF; grades run from A+ (80-100) to F (below 30).
Leadership: Hassan Kotob
CEO
Hassan Kotob serves as the CEO of Brain Scientific Inc. His background includes experience in managing and growing technology-focused companies. He has a track record of leading teams and driving innovation in the medical device sector. Kotob's expertise spans strategic planning, product development, and market expansion. He is responsible for overseeing all aspects of Brain Scientific's operations and executing the company's growth strategy. His leadership is focused on advancing the company's neurology-focused medical devices and expanding its market presence.
Track Record: Under Hassan Kotob's leadership, Brain Scientific has focused on developing and commercializing its NeuroCap and NeuroEEG products. Key milestones include the launch of the NeuroNet Cloud platform and efforts to secure regulatory approvals for new products. Kotob has also overseen the company's strategic partnerships and market expansion initiatives. His focus has been on driving innovation and building a strong foundation for future growth.
BRSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Brain Scientific Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial reporting, and investors should exercise caution due to the increased risk of fraud and manipulation. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, which have stricter listing standards and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher risk of fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Potential delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile and disclosure statements.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Check for any regulatory actions or legal proceedings against the company.
- Development of proprietary technology (NeuroCap and NeuroNet Cloud).
- Focus on a specific niche market (neurology).
- Presence of a CEO with relevant experience.
- Company headquarters in the United States.
- Efforts to secure regulatory approvals for its products.
Brain Scientific Inc. Healthcare Stock: Key Questions Answered
Is BRSF a good stock?
Stock Expert AI does not rate BRSF buy, sell or hold. Brain Scientific Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about BRSF stock?
As of 2026-03-17, there is no available analyst coverage for BRSF stock. Given its micro-cap status and listing on the OTC market, the stock is not widely followed by analysts.
What are the key factors to evaluate for BRSF?
Evaluate BRSF on fundamentals, analyst consensus, and risk factors. A key value driver is the potential adoption of NeuroCap and NeuroEEG by hospitals and clinics seeking more efficient EEG solutions. Not financial advice.
How frequently does BRSF data refresh on this page?
BRSF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BRSF's recent stock price performance?
Brain Scientific Inc. (BRSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative NeuroCap design. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BRSF overvalued or undervalued right now?
Brain Scientific Inc. (BRSF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BRSF?
Yes, most major brokerages offer fractional shares of Brain Scientific Inc. (BRSF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BRSF's earnings and financial reports?
Brain Scientific Inc. (BRSF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BRSF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- OTC market data may be limited and less reliable than data from major exchanges.